Acute myeloid leukemia (AML) is an aggressive hematological malignancy that accounts for majority of acute leukemia cases in adults. Despite recent therapeutic advances, AML is still marked by a dismal prognosis. Our laboratory is interested in understanding mechanisms that govern therapy resistance in hematological malignancies by using CRISPR/Cas9 technology and genetically engineered mouse models.
